Abbott reports first-quarter 2013 results Abbott announced financial outcomes for the first quarter ended March 31, 2013 sildenafil citrate . Worldwide sales of almost $5.4 billion increased 3.5 % on an operational basis, consistent with previous guidance, powered by 9.0 % operational sales growth in Diet and 6.4 % operational sales development in Diagnostics. On a reported basis, sales increased 1.8 %, including an unfavorable 1.7 % aftereffect of forex. Unfavorable exchange was mainly driven by the weakening of japan yen versus the U.S. Dollar. Product sales in emerging markets were $2.2 billion, representing more than 40 % of Abbott’s total product sales, and increased 15.2 % on an operational basis and 13.6 % on a reported basis.
Abbott partnered with Fujirebio Diagnostics, Inc. In the development of the assay. The ARCHITECT HE4 assay is approved for make use of in Europe, along with in other countries in Asia Pacific and Latin America. It is currently an investigational device in the United States. SOURCE Abbott.. Abbott seeks U.S. Authorization for HE4 assay to monitor recurrence/progression of epithelial ovarian cancer A new diagnostic tool physicians can use to monitor patients for the most typical form of ovarian tumor may soon be accessible in the United States. Study of known ovarian tumor biomarkers found that HE4, which has been detected in high amounts in the blood of some ovarian cancer patients, shows the highest sensitivity and specificity of any various other marker and is definitely the best one marker for stage 1 of the condition.